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Abstract 
Given their native-like biological properties, high growth factor retention capacity and porous nature, 
sulfated-polysaccharide-based scaffolds hold great promise for a number of tissue engineering 
applications. Specifically, as they mimic important properties of tissues such as bone and cartilage they 
are ideal for orthopaedic tissue engineering. Their biomimicry properties encompass important cell-
binding motifs, native-like mechanical properties, designated sites for bone mineralisation and strong 
growth factor binding and signaling capacity. Even so, scientists in the field have just recently begun to 
utilise them as building blocks for tissue engineering scaffolds. Most of these efforts have so far been 
directed towards in vitro studies, and for these reasons the clinical gap is still substantial. With this review 
paper, we have tried to highlight some of the important chemical, physical and biological features of 
sulfated-polysaccharides in relation to their chondrogenic and osteogenic inducing capacity. Additionally, 
their usage in various in vivo model systems is discussed. The clinical studies reviewed herein paint a 
promising picture heralding a brave new world for orthopaedic tissue engineering. 
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Abstract 25 
Given their native-like biological properties, high growth factor retention capacity and porous nature, sulfated-26 
polysaccharide-based scaffolds have shown great promise in a number of tissue engineering applications. 27 
Specifically, as they mimic important properties of tissues such as bone and cartilage they are ideal for orthopaedic 28 
tissue engineering. Their biomimicry properties encompass important cell-binding motifs, native-like mechanical 29 
properties, designated sites for bone mineralization and strong growth factor binding and signalling capacity. Even 30 
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so, scientists in the field have just recently begun to utilise them as building blocks for tissue engineering scaffolds. 1 
Most of these efforts have so far been directed towards in vitro studies, and for these reasons the clinical gap is 2 
still substantial. This review paper highlights some of the important chemical, physical and biological features of 3 
sulfated-polysaccharides in relation to their chondrogenic and osteogenic inducing capacity.  Additionally, their 4 
usage in various in vivo model systems is discussed. The clinical studies reviewed herein paint a promising picture 5 
heralding a brave new world for orthopaedic tissue engineering.  6 
1. Introduction 7 
Orthopaedic diseases are the second largest contributor to disability worldwide and are expected to grow 8 
rapidly in the foreseeable future due to the aging population.[1] They include debilitating diseases such as 9 
osteoarthritis, tendinopathies, osteoporosis, as well as skeletal and joint fractures.[2, 3] The current approaches 10 
for addressing this grand challenge rely on various prosthetic, allograft and autograft-based strategies. Even 11 
though the prosthetic-based interventions have shown exciting results in recent years, they still face major 12 
shortcomings such as suboptimal long-term outcomes, the need for revision surgeries and risk of infection.[4] 13 
Allograft and autograft strategies on the other hand impose their own limitations including the possibility of 14 
disease transmission, insufficient autologous resources, rejection of allograft tissue and potential need for 15 
immunosuppression therapies.[5] To overcome these hurdles a great variety of tissue engineering approaches have 16 
been proposed over the years (Figure 1).[3, 6]     17 
The grand goal of tissue engineering is to generate artificial tissues with the capacity to bring normality back 18 
to dysfunctional tissues by replacing them with more functional ones.[4] The tissue engineering paradigm involves 19 
scaffolds combined with potent cell sources and suitable biochemical signals [7], which together can promote the 20 
formation of new organs and tissues.[8] Ideally, these scaffolds emulate key physical and molecular features of 21 
the native extracellular matrix (ECM) in order to facilitate cell attachment, proliferation and differentiation and 22 
ultimately new tissue growth (Figure 1).[9] The key in this regard is to provide the cells with a native-like milieu 23 
with the capacity to guide them into tissue specific phenotypes.[10-13] Generally speaking, bioactivity is included 24 
into scaffolds by using: i) insoluble signals, such as bio-ceramics and carbon-based nanocues [14], ii) introducing 25 
growth factors and other biological moieties into the scaffold matrix [15], or ii) by incorporating cell adhesion 26 
and differentiation promoting oligopeptides (such as the cell binding RGD peptide [16, 17]). 27 
While all of these methods have shown promise in the synthesis of bioactive scaffolds, they still face certain 28 
limitations in the clinic. For instance, i) some insoluble signals such as carbon-based nanomaterials can cause a 29 
foreign body response that can facilitate tissue fibrosis [18, 19], ii) growth factors often face issues such as loss 30 
of bioactivity, low tissue penetration and dosage-dependent toxicity [20] and iii)  many of the bioactive 31 
oligopeptides do not facilitate the needed intracellular signalling pathways for optimum tissue generation; even 32 
though a number of proteins (such as fibronectin[21, 22], collagen[23], osteopontin,[24] vitronectin[25] and 33 
fibrinogen[26]) stimulate much more robust intracellular signalling than bioactive oligopeptides[27-30] they are 34 
limited by either foreign body responses from the host or in some cases high cost and low scalability. For these 35 
reasons, native-like and abundant biopolymers with inherent bioactivity have attracted much attention in 36 
biomaterials science. In particular, sulfated polysaccharides are by now widely recognized for their ability to bind 37 
to important cell receptors to facilitate cell adhesion, proliferation and differentiation.[31, 32] They can also bind 38 
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to and signal a number of important growth factors such as fibroblast, vascular endothelial and bone 1 
morphogenetic protein growth factors for controlled growth factor release; and they can improve growth factor 2 
bioavailability by protecting them against proteinase degradation.[31, 33-36]  3 
In simple terms, sulfated polysaccharides can be classified under three distinct categories including i) 4 
sulfated GAGs, ii) marine sulfated glycans and iii) chemically sulfated polysaccharides. While the first two 5 
categories are inherently sulfated polysaccharides, the third one consists of non-sulfated polysaccharides that are 6 
chemically modified with various sulfating agents. Regardless, the bioactivity of sulfated polysaccharides depends 7 
on factors such as degree of sulfation and sulfation pattern.[34, 37] For instance, hyaluronic acid (HA)/collagen 8 
type I matrices were shown to inhibit differentiation and resorption of osteoclasts, mainly relying on degree of 9 
sulfation of HA.[38] To this end, highly sulfated HA was capable of improving bone regeneration in in vitro and 10 
in vivo models.[39-41] In other studies, an intimate link between sulfation pattern and chondrogenesis has been 11 
proposed.[42] For example, it was shown that chondroitin sulfate (CS) rich in 4,6-O-disulfated disaccharides, had 12 
a higher potential to upregulate the expression of important chondrogenic biomarkers when compared to other CS 13 
derivatives containing either 4- or 6-O-sulfated disaccharides.[42]  14 
Accordingly, sulfated polysaccharides have been rapidly picked up by scientists in the field in order to 15 
manufacture more bioactive scaffolds that can facilitate better skeletal tissue regeneration.[43-53] These scaffolds 16 
were made via various fabrication methods such as casting, electrospinning and 3D printing from either 17 
individually sulfated polysaccharides or in combination with other biopolymers. Generally speaking, the scaffolds 18 
have been used in two different ways to assist osteogenesis or chondrogenesis: i) in conjugation with growth 19 
factors to facilitate differentiation of cells via sustained release of growth factors, or ii) in the absence of any 20 
growth factors by solely relying on intermolecular interactions with important cell-membrane receptors.[54, 55] 21 
This paper reviews the most recent progress in sulfated polysaccharide-based scaffolds for skeletal tissue 22 
engineering, with particular focus on bone and cartilage tissue engineering. Specifically, three different groups of 23 
sulfated polysaccharides, sulfated GAGs, marine sulfated glycans and chemically sulfated polysaccharides, and 24 
their usage as building blocks in orthopaedic scaffolds are reviewed; since these polysaccharides present the most 25 
promising avenues in this field. This review also highlights the ability of these scaffolds to direct progenitor cells 26 
into either chrondogenic or osteogenic differentiation. Finally, application of these scaffolds in various preclinical 27 
studies related to mending bone and cartilage defects along with more complex osteochondral lesions are 28 
reviewed, as such studies are of utmost importance for bridging the current gap between the laboratory and the 29 
clinic.  30 
2. Naturally Sulfated Polysaccharides  31 
Sulfated polysaccharides can be derived from the ECM of animal tissues in the form of sulfated GAGs or 32 
from plants such as marine algae in the form of alginate, carrageenan, fucoidan and ulvan (Figure 2). The sulfate 33 
groups in the abovementioned biopolymers can also be chemically conjugated to the sugar backbones of non-34 
sulfated molecules such as HA, chitosan, alginate and cellulose. Along these lines, this section is divided into 35 
three subsections dealing with sulfated GAGs and polysaccharides derived from natural sources as well as sulfated 36 
polysaccharides that are custom-made in the laboratory. Notably, the wide variety of sulfated polysaccharides 37 
reviewed can display differing bioactivity depending on the sulfate position and degree.   38 
4 
 
2.1 Glycosaminoglycans (GAGs) 1 
Sulfated GAGs are present in the ECM, cellular membrane and intracellularly within eukaryotes (Figure 2). 2 
They therefore, play an essential role in modulating extracellular and intracellular interactions. In simple terms, 3 
GAGs can be defined as negatively charged heteropolysaccharides, whose disaccharide units are made from 4 
repeating disaccharide units consisting of either an amino sugar (glucosamine or galactosamine) or a uronic acid 5 
(iduronic or glucuronic acid). Based on their disaccharide composition, they are grouped into four different 6 
families including heparin/heparan sulfate, chondroitin/dermatan sulfate, keratan sulfate and HA. While heparin, 7 
heparan, chondroitin, dermatan and keratan sulfate are sulfated and post-translationally synthesised via attachment 8 
to a core protein, HA is non-sulfated and synthesised at the cell surface without a protein core. Importantly, GAGs 9 
can differ significantly from one another in terms of bioactivity and structural complexity depending on their 10 
specific biosynthesis pathway and source of derivation.[56]  11 
Heparin and Heparan Sulfate  12 
Heparin is a highly sulfated GAG only produced by connective tissue mast cells that exclusively decorates 13 
the protein core of serglycin. [57] In contrast, heparan sulfates (HS) decorate intracellular, ECM and cell surface 14 
proteoglycans and are produced by almost all cell types. Specifically, they participate in a wide range of biological 15 
events including cell proliferation and differentiation, immune responses, as well as angiogenesis.[58-61] Both 16 
heparin and HS are composed of repeating disaccharide units of either iduronic or glucuronic acid and 17 
glucosamine units but with less iduronic acid and less overall sulfation in HS compared to heparin. Importantly 18 
HS does not contain sulfation at the C3 position and does not possess anti-coagulant activity.[62-64] They also 19 
interact with a variety of proteins, including heparin-binding growth factors, which together with their cell 20 
signalling role, make them ideal choices for scaffolding materials.[60]     21 
Heparin has been widely explored in tissue engineering, owing to its ease of supply, especially in the clinical 22 
as an anticoagulant. It is also often used as an analogue of HS.[65-67] Heparin and HS bind to a range of proteins 23 
via electrostatic interactions that are controlled by its three-dimensional structure, anionic nature and sulfation 24 
patterns. Heparin is known to enhance the osteogenic potential and bioavailability of bone morphogenetic protein-25 
2 (BMP-2) through its binding, stabilization and presentation to cells.[68-70] Indeed, in a study by Hettiaratchi et 26 
al. [71] it was shown that methacrylated heparin microparticles could bind high quantities of BMP-2, vascular 27 
endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2), which in turn could stimulate alkaline 28 
phosphatase (ALP) activity in skeletal myoblasts (C2C12) and increase the cell division rate. Notably, such 29 
heparin microparticles typically demonstrate better presentation of growth factors in comparison to gelatin 30 
microparticles and soluble heparin; something which has been speculated to arise from heparin’s higher charge 31 
density.[71] Similarly, PLGA microspheres when functionalised with both heparin and BMP-2, could 32 
significantly up regulate MG-63 osteosarcoma cell differentiation as seen through the enhanced expression of 33 
osteocalcin (OCN) and osteopontin (OPN), whilst simultaneously increasing both ALP activity and deposition of 34 
important bone minerals.[72] 35 
However, heparin’s anticoagulant capacity can hinder bone regeneration through antithrombin III activation, 36 
which can prevent the accumulation of various tissue regenerative growth factors and cytokines in the defected 37 
bone region. Thus, the lesser negatively charged HS could be a more useful bioactive supplement. To this end, 38 
Bramono et al. [73] compared the osteogenic potential of heparin and HS from various sources; as regulators of 39 
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BMP-2 activity, and found that heparin could up regulate osteogenic differentiation of C2C12 cells (induced by 1 
BMP-2) in the short term, however they did not observe any significant BMP-2 stimulated bone matrix 2 
mineralisation after 14 days. Interestingly, HS delivered BMP-2 in a prolonged and controlled manner, at more 3 
physiologically relevant concentrations whilst retaining its osteogenic activity when compared to heparin. This 4 
was thought to be associated with the higher growth factor binding and signaling capacity of HS compared to 5 
heparin which enables the more efficient presentation of osteogenic ligands to their cell associated receptors.[74] 6 
HS has also been shown to regulate other growth factors in the transforming growth factor beta (TGF-β) 7 
superfamily. For instance, Chen et al. [75] demonstrated that, in the presence of TGF-β3, HS induced 8 
chondrogenic differentiation of human MSCs whilst activating important TGF-β related signaling pathways. 9 
Similarly, heparin in combination with a self-assembling peptide (RAD 16-I) could drive adipose-derived stem 10 
cells (ADSCs) into the chondrogenic lineage as evidenced by collagen type II up regulation; a phenomenon that 11 
was speculated to arise from heparin’s affinity towards VEGF.[76] More recently, a biphasic silk fibroin 12 
biomaterial incorporating heparin was reported to increase growth factor retention and thereby preventing the 13 
undesired initial burst-like release that is so common in many traditional scaffolds.[77] Interestingly, the addition 14 
and controlled release of TGF-β2 and GDF5 (growth differentiation factor 5) into the scaffold up-regulated 15 
chondrogenic markers, including SOX9, aggrecan and collagen type III (Figure 3).  16 
In summary, several studies have demonstrated the versatility of heparin and HS to efficiently deliver and 17 
preserve the function of important chondrogenic and osteogenic growth factors. As mentioned, the prominent 18 
anticoagulant capacity of heparin can diminish the accumulation of growth factors and cytokines in a bone defect 19 
site and subsequently hinder tissue regeneration. HS, the less sulfated heparin analogue, on the other hand holds 20 
promise as an alternate delivery vehicle without such undesirable side effects. In this regard, HS has already 21 
showed promise at permitting sequestration and controlled local delivery of growth factors resulting in an 22 
improved bone and cartilage matrix production. Overall, HS and heparin-based biomaterials have shown immense 23 
promise in multiple branches of tissue engineering including but not limited to growth factor and cytokine delivery 24 
vehicle for bone and cartilage tissue regeneration.  25 
 26 
Chondroitin Sulfate 27 
Chondroitin sulfate (CS) is the most abundant GAG found in vertebrate and invertebrate ECM and decorates 28 
intracellular, ECM and cell surface proteoglycans. It is a linear polysaccharide composed of repeating disaccharide 29 
units of glucuronic acid and galactosamine that can be sulfated at carbons 2 on the glucuronic acid, and 4 and/or 30 
6 on the galactosamine, which provide heterogeneity in structure.[78] Aggrecan is the major CS proteoglycan in 31 
cartilage that binds to HA to form aggregate structures that have a high water retention capacity and provide the 32 
hydrodynamic weight bearing properties of cartilage.[79] CS has been shown to stimulate the synthesis of HA, 33 
aggrecan, glucosamine and collagen II, as well as preventing chondrocyte apoptosis and cartilage degradation by 34 
inhibiting ECM degrading enzymes. Accordingly, CS has been greatly utilized for repairing cartilage as well as 35 
assisting stem cells to undergo chondrogenic differentiation.[80] For a more in-depth analysis of the influence of 36 
CS hydrogels on stem cell fate the reader is referred to a comprehensive review published recently by Farrugia et 37 
al. [81] 38 
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A number of recent studies have harnessed the abovementioned biomimicry properties of CS in cartilage 1 
tissue engineering with exciting outcomes. For instance, a study by Levett et al. [82] aimed to enhance 2 
chondrocyte behaviour in gelatin methacrylate-based (GelMA) hydrogels by incorporating GAGs including HA 3 
methacrylate (HAMA) and CS methacrylate (CSMA) into the hydrogels; both separately and together. 4 
Interestingly, they found that the integration of HAMA enhanced chondrocyte re-differentiation and improved 5 
matrix distribution, whereas CSMA showed marginal improvements over both the GelMA control and 6 
GelMA/HAMA/CSMA triple composite. This means that HAMA positively influences bioactivity and the 7 
mechano-physiological properties of GelMA hydrogels when compared with CSMA. Although, HA provides the 8 
biochemical cues for chondrogenesis, it was shown that the inclusion of CS in the HA hydrogels can upregulate 9 
mRNA expression of chondrogenic markers, while decreasing expression of the hypertrophic markers that are 10 
normally associated with HA hydrogels.[84] Additionally, incorporation of CS into HA hydrogels led to an 11 
increase in GAG accumulation both in vitro and in vivo.  Similar results were observed by Costantini et al. [85] 12 
during bioprinting of bone marrow derived hMSCs in a composite matrix containing GelMA, HAMA and CS 13 
amino ethyl methacrylate (CSAEMA). In the absence of HAMA, the ratio of collagen II/collagen I and collagen 14 
II/collagen X increased suggesting neocartilage formation, whereas differentiation towards hypertrophic cartilage 15 
was observed with HAMA alone. This may be due to the stiffness increase from 59 kPa (GelMA/CS) to 100 kPa 16 
(GelMA/CS/HAMA), as MSC differentiation is sensitive to interface stiffness.[86, 87] In summary, the chemical 17 
composition, network density and stiffness of the 3D microenvironment in combination play an important part in 18 
determining the chondrogenic potential of MSCs, with CS showing the most promising cartilage regenerative 19 
capacity. 20 
CS has also been employed together with other biopolymers such as polyethylene glycol (PEG), chitosan, 21 
and alginate to constitute bioactive scaffolds for cartilage tissue engineering.[46, 88-93] In a noteworthy example, 22 
with the aim of evaluating the effect of CS sulfation degree on its interaction with positively charged growth 23 
factors, researchers made two different types of scaffolds composed of poly(ethylene glycol)-diacrylate (PEG-24 
DA) with either CS or desulfated CS.[89] In vitro experiments demonstrated that the release of a positively 25 
charged model protein, histone, from hydrogels containing desulfated CS resulted in an increased histone release 26 
when compared to a hydrogel containing normal CS, indicating that sulfation plays an essential part in modulating 27 
protein interactions with GAG hydrogels, and thereby also the growth factor release profile. Interestingly, in 28 
chondrogenic medium, MSCs in hydrogels containing desulfated CS had significantly higher expression of 29 
collagen II and aggrecan at day 21, compared to PEG control scaffolds or CS containing scaffolds. This was 30 
speculated to arise from the augmented TGF-β1 pull-down from culture media caused by the presence of CS in 31 
the hydrogels.  32 
 In another study, a biomaterial composed of chitosan and CS was utilized in engineering cartilage 33 
tissue.[46] The in vitro results with a pre-chondrocyte cell line (ATDC5) showed that chitosan/CS induced a more 34 
collagen II/collagen I ratio (a characteristic of hyaline cartilage formation) after 21 days, when compared to 35 
pristine chitosan. Furthermore, the collagen X expression in chitosan/CS showed an increase after 21 days 36 
compared to pristine chitosan scaffolds, indicating that these scaffolds can drive ATDC5 cells into a hypertrophic 37 
state. CS has also been employed in conjugation with alginate to establish porous scaffolds for chondrogenesis of 38 
hMSCs.[93] After 14 days, it was shown that under chondrogenic conditions total collagen and GAG contents 39 
were higher in cells seeded onto CS-containing scaffolds as compared to the CS-free ones. 40 
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Apart from cartilage tissue engineering, CS has been utilized to promote osteoblast adhesion for engineering 1 
of bone tissue.[94] In this respect, Vandrovcová et al. [95] coated PLGA with collagen I with and without CS and 2 
showed that CS improved both the osteoconductivity and osteoinductivity of the (osteoblastic) MG-63 cell line, 3 
observed through the increased proliferation and upregulation of osteocalcin, as compared to pristine collagen I 4 
coatings. Similarly, titanium implants have also been coated with CS/collagen[96] or CS,[97] as sulfated GAGs 5 
are known to bind calcium and calcium phosphates such as hydroxyapatite [98]. The former compared three forms 6 
of CS (4-sulfated CS (CS A); 6-sulfated CS (CS C) and dermatan sulfate (CS B)), and found that both CS A and 7 
CS B stimulated local osteoblast adhesion. We also note, that the study by Dudeck et al. [97] demonstrated a 8 
synergistic effect between CS and hormone replacement therapy in an osteoporotic rat model, and thus indicates 9 
that CS scaffolds could open new therapies for osteoporosis.  10 
In summary, CS has been used in conjunction with biopolymers to form more functional composite 11 
biomaterials that can facilitate both chrondrogenisis and osteogenesis. When used with cartilage forming cells, it 12 
has been seen that the inclusion of CS increases the expression of collagen II, while facilitating a more hyaline-13 
like cartilage formation, as a result of enhanced binding with growth factors and integrin-mediated cell-matrix 14 
interactions the CS structure, and specifically the location of the sulfates on the CS backbone, directly influences 15 
its ability to bind to cells and direct their differentiation. Therefore, CS holds great promise for skeletal tissue 16 
engineering since it can both have an impact on chondrogenesis and bind to important components of the hard 17 
phase of bone; all because of its many sulfate groups. 18 
2.2 Marine sulfated Glycans 19 
Over 70% of the earth’s surface is inundated by oceanic environments, rich in biodiversity. Among these 20 
marine organisms lies algae and seaweed that are abundant with bioactive compounds of use in the field of 21 
biomedicine owing to their numerous health benefits stemming from their anti-inflammatory, anti-cancer, 22 
anticoagulant and immunomodulatory properties.[88, 99, 100] Although seasonal disparities can influence their 23 
overall composition,[101] their sustainable cultivation is not constrained by climate as with various terrestrial 24 
plant species. Notably, some of these algae are also made up of monosaccharides joined by glycosidic bonds 25 
(Figure 2) that resemble GAGs and they can promote protein binding and cell growth without giving rise to 26 
immunogenicity. As with other GAG-like polymers, the bioactivity of sulfated marine sugars depends on their 27 
composition, molecular weight, degree and location of sulfate groups. The three most prevalent marine-based 28 
sulfated polysaccharides currently used in biomedicine are carrageenan, fucoidan and ulvan, derived from red, 29 
brown and green algae, respectively. 30 
Carrageenan 31 
In simple terms, Carrageenans (CARs) can be described as linear and water-soluble anionic-sulfated 32 
polysaccharides. They are derived from red algae of the class Rhodophyceae and identified based on their 33 
disaccharide sulfation. They have previously been successfully exploited in cartilage and bone tissue engineering 34 
applications, owing to their thermoreversible gelling behaviour in the presence of non-toxic cations, as well as 35 
their ability to facilitate bone apatite formation.[102-110]. As a noteworthy example, Popa et al. [102] 36 
demonstrated that kappa (κ) - CAR hydrogels were capable of supporting the proliferation and chondrogenic 37 
differentiation of encapsulated ADSCs. Following 21 days of culture they also observed a raise in hydrogel storage 38 
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modulus and viscoelastic properties possibly related to the ECM deposition from the cells. Additionally, following 1 
compression, hydrogel’s mechanical properties were observed to be in the range of native human cartilage. In 2 
another study, Oliveira et al. [111] investigated how variations in the primary structure of CARs can influence 3 
bone mineralisation. They compared the osteogenic properties of three different CAR sugar backbones, kappa (κ), 4 
iota (ι), and lambda (λ), within a chitosan/polycaprolactone (PCL)-based scaffold. In this respect, it was shown 5 
that bone apatite formation varies significantly between different CAR species. Specifically, of the three CARs 6 
employed, the ι-variant demonstrated significantly higher biomineralization, possibly due to an increased affinity 7 
for various bioactive compounds from the osteogenic media as a result of higher sulfur, oxygen and nitrogen 8 
content within its sugar-like backbone. In a similar vein, the osteogenic capacity of a composite containing ι-9 
CAR/chitosan/gelatin was recently explored.[112] Here, the researchers found that the inclusion of gelatin with 10 
its native RGD peptides and chitosan with its favorable cationic and osteogenic properties,[113] into the CAR 11 
hydrogel network, promoted the osteogenic differentiation of ADSCs. Notably, they found that the inclusion of a 12 
10 wt % ι-CARs substantially increased the ALP activity of encapsulated cells in comparison to the composites 13 
containing 0, 5 and 15 wt % of ι-CAR. Correspondingly, an ostegenic-specific histology assay suggested that the 14 
5 and 10 wt % ι-CAR-based composites caused higher mineral deposits following a 28-day in vitro study than the 15 
other groups. In another recent investigation, κ-CAR was blended into biodegradable polyesthers to consummate 16 
a biocompatible scaffold for bone tissue engineering.[50] Interestingly, the authors found that like the other studies 17 
reviewed herein the presence of κ-CAR could facilitate the formation of nanosized apatite crystals when compared 18 
to pure polyesters, which instead gave rise to non-native-like and larger microsized crystals. Of interest, the 19 
introduction of κ-CAR in the polyester material also enabled tailored degradability. In a related study, Liang et 20 
al. [51] found that the expression of genes specific to cartilage (SOX9, collagen II and aggrecan) were up regulated 21 
with increasing CARs concentrations within chitosan, when compared to pristine chitosan. They also showed that 22 
CARs promoted cellular responses such as adhesion, viability and proliferation in the composite hydrogel. These 23 
benefits were attributed to the chemical similarities between CARs and CS, which is widely recognized for its 24 
chondrogenic capacity.  25 
The thermoreversible and thixotropic gelling behaviour of κ-CAR under physiological conditions also 26 
makes them suitable to be used as injectable hydrogels in cartilage tissue engineering, as evidenced by a recent 27 
study by Rocha et al.[114] Specifically, in this study, it was found that ADSC-laden κ-CAR hydrogels cultured 28 
in TGF-β1 supplemented growth media did not induce chondrogenic differentiation, though when used with 29 
chondrogenic medium, the cells developed a spherical, chondrogenic-like phenotype. Likewise, 30 
immunohistochemical analysis revealed increased collagen II deposition following the integration of TGF-β1 in 31 
the κ-CAR hydrogels under chondrogenic conditions, suggesting the production of cartilage-specific 32 
proteoglycans. Interestingly, the heated gelling conditions did not elicit thermal stress on encapsulated hASCs 33 
following live-dead staining, justifying their potential future use as in situ forming hydrogels in cartilage tissue 34 
engineering.  35 
Fucoidan  36 
Fucoidan is a sulfated polysaccharide stemmed from the cell-wall matrix of brown seaweed. It contains a 37 
significant amount of L-fucose and sulfate ester groups which varies based on the source species.[100] The species 38 
that is most frequently used in the field, is - Fucus vesiculosus - which typically gives rise to Fucoidan consisting 39 
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of 1,2-α-fucose, with its sulfate groups primarily located at C4 position.[115] Interestingly, fucoidan has been 1 
demonstrated to interact with transforming growth factor (TGF)-β1, which was speculated to be associated with 2 
its heparin-like chemical structure,[116] and like the CARs, fucoidan can also facilitate bone-like apatite 3 
formation.[117] Specifically, it was demonstrated that the addition of fucoidan promoted osteocalcin and ALP 4 
production whilst supporting human bone marrow stromal cell (hBMSC) growth. The increase in ALP was 5 
indicative of initial osteogenic differentiation, which happened after a rapid cell division, a stage in osteogenic 6 
differentiation of stromal cells in culture. Interestingly, they also found that fucoidan could more than double the 7 
compressive strength of the scaffolds from 191 ± 5 KPa to 414 ± 3 MPa, something that could come to use later, 8 
due to the intimate link between cartilage/bone formation and biomaterial stiffness.[118] In another study, 9 
Puvaneswary et al. [49] developed a porous fucoidan scaffold to influence bone mineralisation and apatite 10 
formation. These scaffolds promoted hBMSC attachment, proliferation and differentiation. Though the lengthy 11 
process of mineralisation was not significant, upregulation of collagen I under osteogenic conditions demonstrated 12 
osteogenesis within the fucoidan composite. Additionally, Runt-related transcription factor-2 (RUNX2) and 13 
osteonectin (ON) were significantly upregulated compared to the chitosan only hydrogel.  14 
Owing to the TGF-β-binding properties of fucoidan, it was also exploited for cartilage tissue engineering 15 
applications. For instance, Karunanithi et al. [119] studied the chondrogenesis of encapsulated hMSCs within a 16 
fucoidan-alginate composite. The results revealed that hMSCs cultured in chondrogenic medium supplemented 17 
with fucoidan expressed a higher level of chondrogenic markers (including tenascin-C, SOX9, collagen II, 18 
aggrecan and cartilage oligomeric matrix protein). In addition, the cultures expressed a significantly lower level 19 
of hypertrophy markers (including Col X and Runx2), when compared to alginate hydrogels. Furthermore, cells 20 
encapsulated in the fucoidan-alginate hydrogel produced a higher GAG content at day 21 when compared to 21 
alginate hydrogels, which is a widely recognized indicator of mature chondrocyte phenotype. Thus fucoidan may 22 
enhance the chondrogenic differentiation of stem cells owing to its affinity to multiple growth factors, such as 23 
TGF-β1. Likewise, cell condensation – a hallmark for chrondogenic differentiation - were observed in this study, 24 
which puts further emphasis on the promise that Fucoidan holds in cartilage tissue engineering.   25 
Ulvan 26 
Ulvan, a lightly branched anionic-sulfated polysaccharide, is derived from the cell wall of green algae; and 27 
consist of sulfated rhamnose, iduronic and glucuronic acids.[120] The ulvan sugar share a chemical similarity 28 
with GAGs, due to its glucuronic acid and sulfate groups.[88, 121] As with the previously investigated marine 29 
glycans, ulvan has been employed in conjugation with chitosan to generate osteogenic coatings for titanium 30 
implants. To this end, coatings seeded with 7F2 osteoblasts showed complete confluency after 6 days; something 31 
significantly different as compared to cells seeded on pure ulvan or pure chitosan. From this point-of-view 32 
ulvan/chitosan composite induced the attachment and proliferation of 7F2 osteoblasts while maintaining the cell 33 
morphology and viability. In a related study by Dash et al. [122] ulvan was used for bone tissue engineering 34 
applications. Purposely, the group introduced methacrylate groups to the ulvan backbone to further increase the 35 
physiological stability of the hydrogel through UV-crosslinking. Hydrogels were incubated with ALP at varying 36 
concentrations to gauge mineralisation capacity, as mineralisation is known to promote bioactivity through the 37 
formation of chemical bonds with surrounding bone tissue after implantation. The lowest methacrylated-ulvan 38 
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group, saw the highest concentration of ALP resulting in pre-osteoblast cells differentiating towards an osteogenic 1 
lineage, as interpreted from increased ALP activity and a reduction in cell proliferation. 2 
Overall, these naturally sulfated marine glycans have seen limited use thus far in orthopaedic tissue 3 
engineering applications. Since they’re known to have chemical compositions that mimic several ECM-based 4 
GAGs and proteoglycans there’s no doubt they could be used to drive the R&D engine of the next-generation of 5 
biomaterials for orthopaedic tissue engineering. Especially, their strong affinity towards a wide range of tissue 6 
regenerative growth factors makes them ideal growth factor delivery vehicles, which in turn further improve their 7 
tissue regeneration capacity. Additionally, their high abundance and sustainability along with reduced 8 
immunogenicity strongly advocates their promise in the broader field of tissue engineering.  9 
2.3 Chemically sulfated 10 
The biological features of sulfated polysaccharides from mammalian and plant-based sources are vast. In 11 
fact, their bioactivity is a function of molecular weight, sugar-backbone variant and sulfate degree[123] However, 12 
naturally-derived polysaccharides typically give rise to batch-to-batch variations, which further hinders the 13 
reproducibility of their ensuing biophysical properties.[124, 125] As a result, in an effort to produce sulfated 14 
polysaccharides with more specific and controllable functional properties, researchers have started to chemically 15 
manipulate non-sulfated polysaccharides such as HA, chitosan, alginates and cellulose, with either sulfate groups 16 
or sulfate-containing biomolecules. Controlled chemical sulfation of these polysaccharides can be achieved 17 
through various surface immobilisation strategies including chemical binding[126] and electrostatic 18 
assembly.[127] Modifying or combining these polysaccharides with sulfate-containing moieties could exploit 19 
their native chondrogenic or osteoblastic potential whilst prolonging growth factor delivery to promote 20 
proliferation and differentiation of tissue specific stem cells, as well as circumventing shortcomings such as 21 
hypertrophy or rapid enzymatic scaffold degradation.[128]  22 
Hyaluronic acid (HA) 23 
HA is a naturally occurring GAG, that has been widely utilised in tissue engineering as it possesses cell 24 
surface receptors such as CD44 that enable cell binding,[129] and is immunoneutral at the same time.[130] Indeed, 25 
the CD44-based cell binding receptor has been utilised and shown to increase chondrogenesis.[82, 131] Various, 26 
groups have also studied the effect of modifying the HA with sulfate groups, to enable sustained growth factor 27 
delivery through improved growth factor binding. For instance, Xu et al. [132] investigated the effect of decorating 28 
HA with heparin. It was seen that when MSCs were seeded onto a HA-heparin hydrogel with BMP-2 present, 29 
there was significant upregulation of mRNA and key chondrogenic genes including collagen II, SOX9 and 30 
aggrecan, as compared to pristine HA. These improvements can be attributed to the heparin subgroups that contain 31 
sulfate groups, which were seen to have a higher binding capacity for BMP-2. Importantly, a sustained release 32 
profile over 13 days was observed, compared to pristine HA which displayed an initial burst release profile.  33 
In a similar vein, Jha et al. [133] chemically modified HA with HS-bearing perlecan domain I perlecan, a 34 
recombinantly produced proteoglycan. Here, the HA-perlecan hydrogel exhibited the ability to bind significantly 35 
more BMP-2 as compared to HA alone and promoted chondrogenesis. Likewise, Srinivasan et al. [134] 36 
chemically modified HA with HS and demonstrated a targeted and controlled delivery of BMP-2 for cartilage 37 
tissue engineering. For bone tissue engineering HA-based hydrogels have been chemically modified with heparin 38 
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for BMP-2 delivery in vitro and in vivo.[135] In this study a rapid burst release of BMP-2 in non-heparin hydrogels 1 
was observed, with sustained release only seen in heparin containing hydrogels, which in turn maintained the 2 
osteogenic potential of BMP-2 over 28 days. Another study by Hintze et al. [136] compared HA, sulfated HA and 3 
CS hydrogels, and found that, native HA, low sulfated HA and CS showed low affinity for all TGF-β isoforms. 4 
Specifically, the highly-sulfated HA had the greatest affinity for TGF-β1 and TGF-β2 but not TGF-β3.[137] 5 
Overall, HA has proven to be a favorable material for various tissue engineering applications as it contains 6 
the important CD44 receptor and is capable of binding to important tissue regenerative growth factors. Some 7 
studies in the field also suggest that by decorating HA with sulfated materials such as heparin, perlecan and CS, 8 
it is possible to significantly increase its affinity towards important growth factors for skeletal tissue engineering 9 
as well as delaying their release in a controlled manner.  10 
Chitosan 11 
Chitosan is a non-sulfated, linear polysaccharide with a semi-crystalline and biodegradable nature. It’s 12 
typically derived from chitin extracted from insects, crustaceans and fungi (Figure 2). Chitosan is known to have 13 
intrinsic antimicrobial properties against fungi and bacteria.[138] The molecular weight of chitosan varies from 14 
300 – 1000 kD and it is comprised of glucosamine and N-acetyl glucosamine linked by β (1–4) glycosidic bonds. 15 
Notably, chitosan behaves as a polycation under acidic conditions, and thus is capable of forming hydrogels in 16 
the presence of polyanions and polyelectrolytes. Additionally, the degradability of chitosan directly relates to its 17 
degree off crystallinity and can thus be tailored to correspond to the targeted tissue.[139] 18 
To even further improve the already impressive biological properties of chitosan, tissue engineers have 19 
recently tried to modify its polymeric backbone with sulfate groups. For instance, Cao et al. [140] transformed 20 
chitosan into 2-N, 6-O-sulfated chitosan (2,6SCS); and demonstrated that this particular sulfated chitosan is useful 21 
for sustained and dose-dependent BMP-2 delivery among many sulfated variants.[140] In a follow-up study they 22 
made a comparison between BMP-2-gelatin (G)-based scaffolds, BMP-2 loaded 2,6SCS chitosan nanoparticles 23 
(BMP-2/NPs) incorporated into these gelatin scaffolds (BMP-2/S-NP/G) and a BMP2-2,6SCS-G composite. To 24 
this end, the authors found that the BMP-2/S-NP/G variant could significantly prolong the growth factor release 25 
and up-regulate in vitro ALP activity as compared to the other variants (Figure 4); something which was thought 26 
to be associated with the synergistic action of released BMP-2 and the unique material properties of 2,6SCS 27 
sulfated nanoparticles.[141] Interestingly, the addition of nano-particles also had an impact on the mechanical 28 
properties of the scaffold, thereby significantly prolonging its degradation time, to create an optimal condition for 29 
balancing scaffold removal with the deposition of fresh bone tissue. Building on these results, a recent approach 30 
by Pan et al. [142] demonstrated that 2,6SCS can also be used to improve the angiogenic and osteogenic capacity 31 
of BMP-2, confirmed both on a protein and genetic level. In another recent study, Cao et al. used 2,6SCS in 32 
combination with poly(lactide-co-glycolide) (PLGA), to manufacture a composite scaffold (S-PLGA). Here they 33 
demonstrated that the BMP-2 binding efficiency within the PLGA scaffold could increase almost 10-fold in the 34 
presence of 2,6SCS. The release profiles of BMP-2 were 30% slower in S-PLGA scaffolds as compared to pristine 35 
PLGA. In the same study, BMSC cells showed an elongated and spindle-shaped morphology when interacting 36 
with the hydrophilic surface of S-PLGA. Additionally, these cells were seen to circumvent Noggin inhibition, a 37 
BMP antagonist that binds extracellular BMP-2, which in turns inhibits important receptor interactions ultimately 38 
leading to reduced osteogenic capacity. Modification of the chitosan backbone with arginine yields a water-39 
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soluble molecule that is able to interact efficiently within the biological environment in contrast to the acid soluble 1 
starting material. Sulfate modification of this molecule has been achieved at the 2N as well as C2, C3 and C6 2 
positions on the chitosan backbone.[143, 144] These sulfated derivatives bind and signal members of the fibroblast 3 
growth factor family replicating the activities of HS. While chitosan-arginine has been reported to induce 4 
osteogenesis in primary chondroblasts without exposure to osteogenic medium, sulfated chitosan-arginine could 5 
facilitate chondrogenesis  instead.[143] These data demonstrate how subtle changes in sulfation affect cell 6 
phenotype and can direct stem cell differentiation. 7 
In summary, the high abundance of chitosan in nature along with its favorable biocompatible and 8 
biodegradable properties makes it an attractive biomaterial for skeletal tissue engineering. The modification of 9 
chitosan with sulfate groups can further improve the already amazing bioactivity of this material. Indeed, the 10 
controlled introduction of sulfate groups onto chitosan’s backbone can expand its use as a potential coagulator 11 
and a growth factor delivery vehicle.[142] Interestingly, the cationic nature of chitosan enables negative GAGs 12 
and proteoglycans to easily be incorporated into such scaffolds to promote better tissue regeneration. What’s more, 13 
sulfated chitosan is in many ways structurally similar to GAGs, and thus share many of the same biological 14 
properties; as its capable of modulating both cell morphology and function – two important hallmarks of cell 15 
proliferation and differentiation.[145, 146]  Overall, these exciting biomaterial properties of chitosan justify it’s 16 
continued usage as a novel biomaterial in orthopaedic tissue engineering applications. 17 
Alginate 18 
Alginate is a sustainable polysaccharide extracted from brown algae (Pheaophyceae) and less frequently 19 
from gram-negative bacteria (Azotobacter and Pseudomonas sp.). Alginates are linear-anionic polymers with 20 
favorable biocompatibility for various tissue engineering applications (Figure 2).[147, 148] Notably, alginate has 21 
the capacity to form ionic hydrogel networks through chelation with divalent cations, such as Ca2+, broadening its 22 
use towards drug delivery[149]. Additionally, due to the innate adhesive and tailorable shear thinning viscoelastic 23 
properties of alginate it has found widespread use in bioprinting applications.[150-152] As with other plant-based 24 
hydrogels, alginate does not natively support cell adhesion and has been described as a “blank slate” by many 25 
engineers in the field.[153] Even still, alginate can be customised through sulfation and peptide modifications to 26 
control the phenotypes of encapsulated osteoblasts,[154] chondrocytes[155] and hMSCs.[156]  27 
Alginate sulfation based on sulfur trioxide (SO3) [157] and sulfuric acid[158] treatments have been widely 28 
used over the years. To this end, some studies have demonstrated that such sulfated alginates can retain growth 29 
factors and promote chondrogenesis through various cellular signaling pathways;[159] and for these reasons they 30 
are considered as heparin analogues (Figure 5). Along these lines, Mhanna et al. [160] employed an SO3/pyridine 31 
method of alginate sulfation for cartilage tissue engineering. In this study, the formation of ionic networks was 32 
restricted to a degree of sulfation of 0.8 (per monosaccharide unit), as higher degrees of sulfation (2.6) did not 33 
facilitate hydrogel formation, possibly due to strong electrostatic forces and/or steric effects between adjacent 34 
polymers. Interestingly, they found that sulfation maintained the proliferative capacity as well as phenotype of 35 
encapsulated chondrocytes, in contrast to previous studies showing initial dedifferentiation in a non-sulfated 36 
hydrogel microenvironments.[161-163] The introduced sulfate groups also influenced Ras homolog gene family 37 
member A (RhoA) activity, which is known to be associated with chondrocyte proliferation and 38 
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differentiation[164]; though the expression of collagen I and collagen II as well as proteoglycan synthesis was not 1 
significantly impacted.  2 
Thus, sulfated alginate-based scaffolds are promising alternatives to mammalian derived GAGs due to their 3 
biocompatibility, low immunogenicity, protein retention capacity and the great variety of readily implementable 4 
gelling and functionalisation strategies that can improve their bioactivity. Their extensive and continued use will 5 
definitely empower researchers with the knowledge to effectively understand the regulatory role of sulfated-6 
alginate in extracellular and intracellular interaction, something, which hopefully will lead to their more frequent 7 
use in skeletal tissue engineering in the foreseeable future.  8 
Cellulose 9 
Cellulose is the most abundant natural polysaccharide available in the world.[165, 166] Its chemical 10 
structure consists of unsubstituted, linear glucose homosaccharide with six available hydroxyl groups. 11 
Intriguingly, it has been seldom used in tissue engineering, potentially due to difficulties in hydrogel assembly 12 
caused by solubility inadequacies.[167] The sulfation of cellulose can improve solubility, through the disruption 13 
of intermolecular hydrogen-bonds[168] to potentially broaden its applicability towards various tissue engineering 14 
applications.[169] 15 
One study by Huang et al. [170] explored the use of sulfated cellulose scaffolds for cartilage tissue 16 
engineering. Initially MSC induction media was spiked with a fully sulfated form of sodium cellulose (NaCS) 17 
leading to a significant upregulation of collagen II and aggrecan. In the same study, NaCS was combined with 18 
gelatin to develop scaffolds through electrospinning. Interestingly, the scaffolds with the lowest concentration 19 
(0.1%) of NaCS added to induction media resulted in the highest production of collagen II both on a protein and 20 
genetic level after 56 days of culture. Additionally, cells on the 1% and 5% NaCS/Gelatin-based scaffold showed 21 
low collagen X production, suggesting higher NaCS may result in a reduced propensity towards hypertrophy. 22 
These higher sulfate concentrations may have an inhibitory effect on chondrogenesis because of irreversible 23 
growth factor-biomaterial bindings, which in turn can comprise the release and delivery of TGF-β3 to the targeted 24 
cells.[171] The same group took this a step further and introduced partially sulfated cellulose (pSC) into gelatin 25 
hydrogels instead, and discovered an enhanced expression of chondrogenic markers (collagen II/collagen I ratio, 26 
aggrecan and SOX9) upon increasing pSC concentration in the scaffolds, indicating the potential of pSC as a 27 
scaffold for cartilage tissue engineering.[172] 28 
 For these reasons, cellulose sulfate is an interesting carrier for growth factor delivery in cartilage tissue 29 
engineering and could have broader uses in the foreseeable future due to its abundance, sustainability and reduced 30 
immunogenicity. Specifically, the backbone sulfation of cellulose allows for precise control over the sulfation 31 
pattern and sulfation degree, and thereby enables the biological properties of such scaffolds to be fine-tuned in a 32 
customizable manner. The range of available chemical modifications can also pave the way for tuneable 33 
mechanical and pharmaceutical properties, and could thereby potentially enable an even greater variety of 34 
biomaterials. [173] [174] 35 
3. Tissue engineering 36 
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While sulfated polysaccharides have been shown to successfully act as delivery vehicles for growth factors 1 
in an in vitro environment, their ability to elicit this response in an in vivo model needs to be evaluated as well. 2 
Indeed, many tissue engineering approaches have shown significant benefits in in vitro studies yet when they 3 
progress to animals models they show some limitations.[28] Understanding, whether the successful in vitro 4 
strategies also show promise in an in vivo setting, is therefore critical to successfully translate tissue engineering 5 
strategies from the laboratory and into the clinic. This section, highlights recent advances in translating the hard 6 
tissue regenerative potential of scaffolds made from sulfated polysaccharides in various animal models both alone, 7 
in combination with various growth factor or with other biopolymers.  8 
3.1 Bone 9 
 The number of people at risk of bone fractures has grown steadily in most parts of the world due to the 10 
ageing population. In 2015 around 160 million people worldwide experienced a bone fracture; a number that is 11 
expected to double to 320 million by the end of 2040.[175] Traditional clinical therapies for mending bone 12 
fractures rely on various forms of casts to fixate the broken fracture to enable the native bone to heal itself on its 13 
own terms, however, native bone displays a restrictive regenerative capacity, that is haunted by a number of 14 
challenges including non-anatomical reduction of the fracture, a-vascular necrosis, as well as non-union and mal-15 
union fracture healing.[176] These issues are more prevalent in older people and will thus grow steadily in the 16 
near future as the median lifetime is expected to increase significantly in the coming decades. Autologous bone 17 
grafts are commonly utilized to promote osteoconduction and osteoinduction in bone defects to avoid the 18 
abovementioned scenarios. While these grafts have shown some promise for healing bone defects, they require 19 
multiple invasive surgeries and are hindered by low availability and donor site morbidity associated with 20 
relocating native bone tissue from the patient’s own bone and into the defect site.[177] Allografts on the other 21 
hand are limited as a consequence of lack of available donor tissues and unwanted foreign body responses; and 22 
bone implants in some cases do not facilitate sufficient bone healing and therefore revisions surgeries are common 23 
with this methodology.[178]  24 
For these reasons, a number of bone tissue engineering strategies have emerged to address this critical 25 
challenge by delivering the promise of a better method to mend bone defects.[179] As such, these approaches rely 26 
on developing synthetic bone tissues by combing 3D biomaterials with stem cells either exogenously or by 27 
recruiting them from native bone-tissue in a post-implantation scenario. The 3D biomaterials have the potential 28 
to drive stem cells into bone-like cells that under the right conditions can form mature tissues either in the 29 
laboratory or within the body depending on which one of the abovementioned strategies has been employed 30 
(Figure 1). However, many of the tissue engineered scaffolds explored to date have not reached this full potential 31 
and in many cases fall short of the performance of autografts.[180] A number of studies, including those by Wang 32 
et al. [177] and Lee et al. [15] suggest that such results could be related to the uncontrolled release of growth 33 
factors that collaterally interfere with untargeted cells. As sulfated polysaccharides can bind and regulate the 34 
signalling of a number of important growth factors they are likely to be essential components of next-generation 35 
biomaterials for bone tissue engineering.  36 
Indeed, sulfated polysaccharides are considered one of the most important biological and mechanical 37 
components of the native ECM of hard tissues.[181] They have therefore in recent years emerged as new and 38 
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promising building blocks for bone tissue engineering scaffolds.[182] Heparin is one of the most widely employed 1 
sulfated polysaccharides in this respect, due to its ability to capture, stabilize and present growth factors to bone 2 
progenitor cells in a controllable manner. For instance, Yang et al. [183] developed heparin‐conjugated fibrin 3 
scaffolds for orthotopic in vivo models to control the release of BMP-2 in order to prolong the bioactivity of ALP. 4 
This prolonged activity ultimately translated itself into significant improvements in bone mineralization when 5 
compared with pristine fibrin scaffolds. Notably, by using heparin, they were able to obtain a similar amount of 6 
new tissue formation with lower concentrations of BMP-2 than previously reported in the literature.[184] 7 
However, some studies have reported that exogenous heparin under certain circumstances reduces the bioactivity 8 
of osteogenic biomolecules and can thus compromise the bone healing process, by inhibiting the binding of BMP-9 
2 to the BMP receptor. What’s more, the potent anticoagulant activity of heparin is, by many in the field, thought 10 
to be counterproductive for bone growth.[185] 11 
To address these issues, sulfated chitosan, has been used as an alternative due to its good biocompatibility 12 
and similar growth factor binding ability as heparin without the abovementioned native biological issues 13 
associated with heparin.[186] In this direction, Zhou et al. [187] synthesized BMP-2 loaded chitosan with varying 14 
degrees of sulfation and compared their responses in vivo. These in vivo results revealed that the most sulfated 15 
chitosan-based scaffold was the best promoter of BMP-2 bioactivity, and could even surpass the bone regeneration 16 
capacity of heparin-based scaffolds. Similarly, Bai et al. [188] and Lü et al. [189]  developed a self-healing, 17 
biocompatible and injectable dual cross-linked CS-based hydrogels for in vivo delivery of BMP-4.  This hydrogel 18 
was crosslinked through both diels-alder (DA) and acylhydrazone bonds; and the authors used these bonding 19 
schemes to fine-tune various hydrogel properties such as rigidity and degradation. Through this sophisticated 20 
crosslinking scheme they were also able to manufacture a superior hydrogel, which could prevent excessive 21 
hydrogel swelling in vivo; and thereby prevent poor stem cell differentiation and tissue regeneration.[190] In both 22 
instances, histology staining’s demonstrated new bone formation in the BMP-4 loaded hydrogel samples after 12 23 
weeks, with controls primarily stimulating fibrous tissue growth. Additionally, initial sproutings of blood vessels 24 
were observed. In another noteworthy study, Kim et al. [181] evaluated the inclusion of UV-crosslinked 25 
methacrylated CS (MeCS) in PEGDA hydrogels at various concentrations in terms of their bone regenerative 26 
properties within the body (Figure 6). Specifically, these scaffolds were implanted in critical sized calvarial defects 27 
(4mm diameter) in six-week-old female mice (n = 4) for up-to eight weeks. Interestingly, scaffolds containing the 28 
highest concentration of CS induced the most effective bone formation evidenced by larger bone mineralization 29 
density. This was speculated to arise from the ability of the sulfate groups within CS to bind to calcium ions and 30 
facilitate the formation of fresh hydroxyapatite; one of the most important components of the mineral phase of 31 
bone. Additionally, Hematoxylin, Eosin and Masson's trichrome staining’s also showed significant improvements 32 
in bone tissue formation with increasing CS concentration. 33 
Although, a wide range of sulfated polysaccharides have been studied in the literature, these biomaterials 34 
are seldom employed in clinical treatments due to the lack of more standardized clinical studies.[191] Indeed, a 35 
number of important parameters such as the size of the bone defect, the place of the defect, the implanted cell 36 
type, and implantation time needs to be considered to fully unravel the bone tissue engineering potential of such 37 
scaffolds. Unfortunately, these parameters have not been studied enough to turn this promising strategy into a 38 
clinical therapy which can benefit the many sufferers of bone disorders.[191] Consequently, more in-depth in vivo 39 
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studies are necessary to validate the efficiency of sulfated polysaccharides for bone tissue engineering, and to 1 
identify the best combination to use in the clinic.  2 
3.2 Cartilage 3 
The primary cause of cartilage damage within the body is due to osteoarthritis (OA) in articular cartilage. 4 
The clinical treatment for OA is currently suboptimal as the “state-of-the-art” surgical approaches are limited in 5 
terms of their efficacy and high invasiveness. First stage interventions include arthroscopy, which involves the 6 
flushing and removal of damaged cartilage and meniscus.[192] For more severe cases, the implantation of 7 
autologous osteochondral graft (mosaicplasty) into the defect site and surgical drilling into the subchondral bone 8 
(microfracturing) can be employed.[193] However, unfortunately both measures are controversial as they often 9 
result in fibrous cartilage rather than native articular cartilage.[194] For the most severe cases, extremely invasive 10 
and costly total knee replacements can be performed.[195] Notably, these measures are aimed at slowing the 11 
impact of OA without actively regenerating native cartilage.  12 
Recently, techniques such as stem cell therapy have been used to regenerate cartilage tissue, by injecting 13 
regenerative cells into the damaged region.[43, 48, 174, 196] This technique is limited by low cell retention and 14 
a low cell viability, caused by the shear-forces that cells experience when passing through the thin injection needle. 15 
It also does not provide the cells with a 3D microenvironment to properly differentiate them into the required 16 
tissues. The usage of hydrogels can provide a mechanical shield during the needle-injection phase and provide a 17 
proper 3D microenvironment for guiding cells into the desired cell phenotypes in a post-injection scenario.  18 
Especially, sulfated hydrogels hold great promise in this respect, since they display high affinity towards important 19 
growth factors for cartilage regeneration; and in many ways resemble – CS - one of the most important 20 
components of the native cartilage ECM. Indeed, such biopolymers have recently been used to develop scaffolds 21 
with the capacity to deliver growth factors such as BMP-2 and TGF-β3 in a sustainable manner to significantly 22 
improve the cellular performance of chondrocytes.[75, 76] In another related study by Han et al. [197] a mussel 23 
inspired CS-based hydrogel was created for enhanced adhesion between graft and native cartilage tissue (Figure 24 
7). Specifically, the inclusion of CS promoted an upregulation of chondrogenic differentiation markers such as 25 
aggrecan and collagen II. The scaffolds were also evaluated in a full thickness defects (diameter: 3.5 mm; 26 
thickness: 5 mm) in the patella groves in the right legs of white rabbits (n = 8). Following a three-month 27 
implantation period, the scaffolds showed significantly higher tissue formation in terms of Modified O’Driscoll 28 
and International Cartilage Repair Society grading scores.  29 
The abovementioned studies on using sulfated polysaccharides for cartilage regeneration clearly 30 
demonstrate the great promise that they hold for the field of cartilage tissue engineering. Indeed, considering the 31 
importance of cell therapy in treating acute cartilage injuries, sulfated polysaccharides can be ideal scaffolding 32 
materials to support the chondrocytes temporarily until the implanted cells replace them by matrix components. 33 
Collectively, the use of such scaffolds is expected to reduce chondrocyte leakage from the transplant site, facilitate 34 
a more homogeneous chondrocyte distribution, and diminish graft hypertrophy.[198] Regardless, if these 35 
scaffolds were to be used in cartilage tissue engineering, we would need to consider important parameters such as 36 
lesion location and damage size, activity level and patient’s age. These parameters are by many in the field 37 
considered the important parameters when it comes down to deciding which cartilage repair approaches to use 38 
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and evaluating the treatment.[199] Finally, the biomaterials utilised in in vivo cartilage tissue engineering need to 1 
demonstrate appropriate biomechanical and biochemical cues without triggering immune responses. Therefore, 2 
biomaterials and cell therapy techniques should also be compared to ‘gold standard’ techniques such as 3 
microfracture and grafting in order to accurately gauge their efficacy in vivo. The continued investigations into 4 
the usage of sulfated polysaccharides as growth factor delivery vehicles is also needed to fully elucidate their 5 
potential as tissue engineering scaffolds for cartilage regeneration. 6 
3.3 Osteochondral  7 
Defects that impact both the articular cartilage and the underlying subchondral tissues are termed 8 
osteochondral defects. Such lesions are caused by tissue degradation from aging, sports injuries or severe cases 9 
of osteoarthritis. They typically result in joint instability, significant discomfort for the patient and loss of patient 10 
mobility. Much like cartilage, osteochondral defects can be treated through microfracturing, allografting and 11 
mosaicplasty, or even total knee replacements, however, all of these therapies unfortunately have similar issues 12 
as those briefly mentioned in the previous section.[200] The abovementioned tissue engineering approaches could 13 
remedy these shortcomings by recapitulating the highly hierarchal structure of osteochondral defects.  14 
  In this direction, Zhou et al. [201] recently combined silk fibroin with CS to develop a composite scaffold 15 
that could mend osteochondral defects in a rabbit animal model. Indeed, this composite material produced greater 16 
neo-tissue formation and improved structural restoration compared to the pristine silk scaffold at 6 and 12 weeks 17 
as evident from an International Cartilage Repair Society histological analysis (Figure 8). Additionally, when 18 
analysed in vitro, the composite scaffold was seen to maintain better chondrocyte morphology compared to the 19 
silk scaffold alone, in combination with a higher expression of SOX9, collagen II, aggrecan and lower expression 20 
of TNF-2 (an important inflammation marker) (Figure 8). In a similar vein, Liao et al. [202] implanted a 21 
biomaterial composite consisting of methacrylated CS and poly(ethylene glycol) methyl ether-ε-caprolactone-22 
acryloyl chloride (MPEG-PCL-AC) incorporated with graphene oxide, into full-thickness osteochondral defects 23 
(thickness: 3mm, diameter: 4mm, n = 27) in the hind limbs of rabbits. When combined with chondrocytes, the 24 
scaffold was seen to improve chondrocyte morphology, integration, and subchondral bone formation. Notably, 25 
this strategy could rapidly induce the formation of both new and thicker cartilage tissue as compared to a cell-free 26 
scaffold.  27 
In another study Feng et al. [52] conjugated sulfate groups onto the backbone of methacrylated hyaluronic 28 
acid (MeHA) in order to deliver growth factors in a osteochondral rodent (n = 10) model in a controlled and 29 
sustainable manner (Figure 9). Typically, HA is degraded rapidly by hyaluronidases in vivo and lacks high protein 30 
binding affinity. They found that the introduction of sulfate groups reduced the degradation and deformation of 31 
hydrogel scaffolds and promoted cartilage matrix deposition, as indicated by immunohistochemical stainings of 32 
collagen II and CS, following 4 weeks in vivo studies. Additionally, the sulfated-HA in combination with hMSCs 33 
was capable of attracting and retaining supplemented TGF-β1, and thereby promoting chondrogenesis and 34 
suppressing hypertrophy. Overall, the paper by Feng et al. [52] demonstrates that sulfated HA hydrogels enable 35 
the generation of high quality neocartilage via intra-articular injection. Another noteworthy study used a heparin 36 
immobilised polycaprolactone (PCL)/Pluronic F127 scaffold combined with TGF-2 and BMP-7 to facilitate even 37 
more cartilage tissue formation as compared to PCL/Pluronic scaffolds alone. However, no significant histological 38 
18 
 
differences following implantation into large (diameter = 6mm, depth = 3mm) distal femur defects in rabbits (n = 1 
12) was seen in this study.[203] Finally, Re’em et al. [204] recently created a bilayer scaffold with alginate-sulfate 2 
incorporating both TGF-β2 and BMP-4. This scaffold was subsequently implanted into subchondral defects 3 
(diameter = 3mm, depth = 3mm) in the femur of rabbits. Encapsulated hMSC’s were successfully differentiated 4 
into both osteoblasts and chondrocytes at respective layers over 4 weeks, confirming the controlled release of the 5 
growth factors. Additionally, the cartilage–bone interface formation remained the same in hMSC incorporated 6 
scaffolds, indicating that native cells were able to migrate into the scaffolds and sense the biological cues spatially 7 
present in there, and respond accordingly by differentiating to the appropriate cellular lineage.  8 
History has shown that applying promising laboratory strategies to animal models is not always as 9 
successful. Even a rudimentary understanding, through the use of pilot studies, of the in vivo efficacy of such 10 
techniques can create a much more efficient process for producing novel, viable tissue engineering solutions. For 11 
these reasons, sulfated-scaffolds for osteochondral tissue engineering are also beginning to be translated into in 12 
vivo environments. Most often, these materials are used in composites to capitalise upon the benefits of multiple 13 
materials and to develop the hierarchical scaffolding architecture needed for optimal ostechondral repair. To this 14 
end, the effects of growth factor delivery and improved cellular performance observed in in vitro studies appear 15 
to translate into in vivo outcomes. Additionally, the studies reviewed here indicate that sulfated polysaccharide do 16 
not elicit any significant inflammatory responses when implanted in vivo, confirming that they indeed are suitable 17 
biomaterials for osteochondral tissue engineering.  18 
Conclusion and future directions 19 
Tissue engineering has shown tremendous potential in several facets of biomedicine, particularly in skeletal 20 
tissue engineering. With the ongoing development of novel sulfated biomaterials along with sophisticated in vitro 21 
culturing systems tissue engineering will enhance our capacity to recapitulate bone and cartilage regeneration 22 
through the sustained delivery of relevant growth factors. Overwhelmingly, the most commonly studied and 23 
successful naturally sulfated biomaterials include CS and heparan sulfate and its analogues. The benefits that these 24 
naturally sulfated ECM components provide can be chemically incorporated into non-sulfated biomaterials. 25 
Specifically, HA and chitosan sulfation allows for the controlled binding and release of growth factors in a 26 
localised environment. The use of composite materials in tissue engineering is omnipresent and can capitalise 27 
upon the benefits of multiple materials. These four materials, CS, Hep/HS, HA and chitosan, can be easily utilised 28 
in a composite system, where the scaffold can provide cells with controlled, prolonged and protected growth factor 29 
delivery. Though, the translational capacity of animal-derived sulfated biomaterials is limited in vivo due to 30 
immunogenicity, further exploration into plant-derived substrates could be a worthy endeavour. Intriguingly, as 31 
these materials don’t have specific enzymes for degradation their use could potentially extend growth factor 32 
delivery beyond the body’s native capacity. Many areas within the vibrant field of tissue engineering could readily 33 
benefit from the utilization of sulfated biomaterials as a vehicle for providing growth factors to the target tissues 34 
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Figure captions 20 
 21 
Figure 1: A schematic showing the core-principles behind tissue engineering. 22 
 23 
Figure 2: Some of the most important sulfated polysaccharides reviewed herein have been 24 
highlighted in this figure along with their derivation source and chemical structure. 25 
 26 
Figure 3: The growth factor retention capacity of heparin. (a) Schematic showing the 27 
design principle behind the biphasic silk fibroin scaffold used in the study. (b) The heparin 28 
loading efficiency and its release profile from the scaffold in displayed here. (c) The sustained 29 
release of TGF-2 and GDF5 is displayed here. Crosslinked heparin significantly delayed the 30 
growth factor release. Modified from[77], with permission from Elsevier, Copyright 2018.  31 
Figure 4: The growth factor retention capacity of sulfated chitosan. (a) Schematic 32 
showing the design principle behind the S-NP incorporated gelatin scaffolds. (b) The size 33 
distribution and scanning electron microscopy images (SEM) of the S-NP’s are displayed here. 34 
(c) The sustained release of BMP-2 from the scaffolds employed in this study is displayed here. 35 
Modified from[141], with permission from Elsevier, Copyright 2014. 36 
32 
 
Figure 5:  A schematic showing the growth factor bind properties of sulfated alginates and 1 
their ability to promote chrondogenesis through important signalling pathways. Modified from 2 
[159], with permission from MDPI, Copyright 2017. 3 
Figure 6:  A chondroitin (CS)-based scaffold for bone tissue engineering. (a) The 4 
manufacturing of the PEGDA-MeCS hydrogel and its hydroxyapatite (HAP) formation 5 
capacity is shown here. (b) The calcification and HAP formation of the cell-laden hydrogels 6 
after 21 days are shown here through photographic images of the hydrogels at relevant time 7 
points. (c) The bone regenerative capacity of the respective scaffolds incorporating different 8 
concentrations of CS was quantified through Micro-CT analysis after 8 weeks of implantation. 9 
(d) The bone area (BS/TS) and bone volume (BV/TV) were also calculated and are displayed 10 
here. Adapted with permission from [181]. Copyright (2017), American Chemical Society. 11 
 12 
Figure 7: A tissue adhesive CS-based scaffold for cartilage tissue engineering.  (a) The 13 
CS-based scaffold was made tissue adhesive by polymerizing dopamine (DA) and acrylamide 14 
(AM) into it. (b) The tissue adhesive properties of the scaffold was mediated by the many 15 
amino groups present on PDA and PAM. (c) The adhesion strength of the various manufactured 16 
scaffolds towards porcine skin is shown here. (d) The cartilage regenerative potential was 17 
highest for the PDA-CS-PAM hydrogel. (e) This was further validated by analysing the 18 
Modified O’ driscoll scoring for the implanted scaffolds after 3 months of implantation. 19 
Adapted with permission from [197]. Copyright (2018). American Chemical Society.  20 
Figure 8: A Silk-CS-based scaffold for osteochondral tissue engineering.  (a) The 21 
manufacturing process behind the Silk-CS scaffold is shown here. (b) The chrondrogenic and 22 
anti-inflammatory capacity of the Silk-CS was quantified from expression of relevant gene 23 
markers. (c) Histological evaluation of the scaffolds after 12 weeks of implantation. H&E is 24 
short for hematoxyling and eosin and SO for Safranin O. (D) The histological scores for 25 
subchondral bone formation was evaluated after 6 and 12 weeks. Modified from [201], with 26 
permission from Elsevier, Copyright 2017. 27 
 28 
Figure 9: A sulfated hyaluronic acid scaffold for osteochondral tissue engineering. (a) 29 
The manufacturing scheme behind the scaffolds are shown here, where LS-MeHA and HS-30 
33 
 
MeHa are short for low sulfated and high sulfated methacrylated hyaluronic acid (HA), 1 
respectively. (b) The TGF-1 retention capacity of the various scaffolds employed in the study 2 
is shown here.  (C) Histological staining of the respective hMSCs-laden scaffolds after 42 days 3 
of implantation. Modified from [52], with permission from Elsevier, Copyright 2017.  4 
